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WHAT THIS PAPER ADDS?
 Although restenosis after plain angioplasty for infrapopliteal lesion occurs at a high rate because of the generally long and diffuse
nature of arteriosclerotic disease in this region, the impact of restenosis on patient and limb prognosis after angioplasty has not
been systematically studied. Therefore, our study assessed the angiographic restenosis rate 3 months after infrapopliteal angio-
plasty and evaluated the impact of early restenosis on clinical outcomes in patients with critical limb ischemia after infrapopliteal
angioplasty. Although the subsequent occurrence of restenosis has been considered not to affect limb salvage, leading to a perceived
lack of relevance of durability of infrapopliteal angioplasty in the clinical setting, results from this prospective multicenter registry
indicate that occurrence of angiographic restenosis after angioplasty in critical limb ischemia patients is extremely high in the early
phase and adversely affects clinical outcomes at 3 and 12 months.a r t i c l e i n f o
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Objective: To assess 3- and 12-month angiographic restenosis rates and their clinical impact after
infrapopliteal angioplasty.
Design: Prospective multicenter study.
Materials and methods: We analyzed 68 critical ischemic limbs (tissue loss: 58 limbs) from 63
consecutive patients due to isolated infrapopliteal lesions who underwent angioplasty alone. Primary
endpoint was 3-month angiographic restenosis rate; secondary endpoints were 12-month angio-
graphic restenosis rate, and 3- and 12-month rates of mortality, major amputation and reintervention.
Three- and 12-month frequency of ambulatory status and of freedom from ischemic symptoms, and
time to wound healing in the ischemic wound group, were compared between restenotic and non-
restenotic groups. Angiographic restenosis predictors were assessed by multivariable analysis.
Results: 95% of cases had 3-month angiography; restenosis rate was 73%: 40% restenosis and 33% re-
occlusion. Twelve-month follow-up angiography was conducted for the patients without 3-month
angiographic restenosis, and restenosis rate at 12 months was 82%. Non-administration of cilostazol and
statin, and chronic total occlusionwere 3-month angiographic restenosis predictors. Three- and 12-month
mortality was 5% and 12%, respectively. Despite no patients having undergone amputation, 15% had
persistent ischemic symptoms, and 48% of limbs underwent reintervention within 12 months. During the
same study period, ambulatory status and limbs with complete healing were more frequently observed in
the non-restenosis group than in the restenosis group. In the tissue loss group, time towoundhealing in the
restenosis group was longer than in the non-restenosis group (127 days vs. 66 days, p ¼ 0.02).
Conclusion: The extremely high angiographic restenosis rate after infrapopliteal angioplasty may
adversely impact clinical status improvement.
Crown Copyright  2012 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery. All
rights reserved.012 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery. All rights reserved.
and Endovascular Surgery 44 (2012) 425e431Introduction hemodynamic status in lower limb ischemia, ankle-brachial index
(ABI) and skin perfusion pressure (SPP) were measured. SPP wasO. Iida et al. / European Journal of Vascular426Long-term durability and a high limb salvage rate have made
surgical bypass therapy (BSX) the standard treatment modality for
patients with critical limb ischemia (CLI)1,2 In the BASIL (bypass vs.
angioplasty in treatment of severe leg ischemia) trial on CLI patients
with infrainguinal arterial occlusive disease, a revascularization
technique (BSX or EVT)was recommended based on the presence of
useable vein and life expectancy.3,4 However, in clinical practice,
these patients are often not suitable surgical candidates due to
concomitant disease and advanced age,which has ledmany to favor
endovascular therapy (EVT) as ﬁrst-line therapy in this high-risk
target population.5e7 Recently, similar amputation-free survival
rates inpatientswith CLI due to infrapopliteal lesionswere observed
for the two revascularization strategies after propensity matching
analysis.8 However, restenosis after plain angioplasty for infrapo-
pliteal lesion occurs at a high rate because of the generally long and
diffuse nature of arteriosclerotic disease in this region, and a recent
trial also documented that restenosis of extensive infrapopliteal
disease occurs in the early phase.9 However, the impact of restenosis
on patient and limb prognosis after angioplasty has not been
systematically studied. Also, the 12-month angiographic restenosis
rate remains unknown. Therefore, our study objective was to assess
the 3- and 12-month angiographic restenosis rate after infrapopli-
teal angioplasty, and to evaluate the clinical impact of restenosis on
the prognosis for patients with CLI after infrapopliteal angioplasty.Methods
Participants
Participants were enrolled from January to March 2011 in this
prospective multicenter registry study. During this period, 235
limbs in 216 consecutive CLI patients were treated with EVT in one
of six cardiovascular or vascular centers in Japan. The database
included 68 limbs from 63 consecutive patients who successfully
underwent angioplasty alone for de novo infrapopliteal lesions, and
who also consented to undergo follow-up angiography at 3months.
All patients were symptomatic secondary to isolated infrapopliteal
lesions (Rutherford 4e6) in critical ischemic limbs. Patients with
CLI due to infrapopliteal lesions combined with femoropopliteal
lesions (54%, 120 limbs in 115 patients) or with ilio-femoral lesions
(14%, 32 limbs in 28 patients) were excluded from this study. Ten
patients (15 limbs) who refused 3-month follow-up angiography
were excluded. Patients who presented with acute limb ischemia
requiring emergent revascularization or functionally unsalvageable
limbs were also excluded from this analysis. BSX was selected by
consensus among vascular specialists. During the study inclusion
period, 26 CLI patients were initially treatedwith bypass therapy by
a vascular surgeon without prior endovascular intervention. The
study protocol was developed in accordance with the Declaration
of Helsinki, and approved by the ethics committees of all centers.
This study was also registered in the University Hospital Medical
Information Network Clinical Trial Registry (UMIN-CTR), whichwas
approved by the International Committee of Medical Journal
Editors (no. UMIN000006488, J-BEAT angio registry: Japanese
BElow-the-knee Artery Treatment for the angiographical assess-
ment registry). All patients gave written informed consent prior to
revascularization.Protocols
After admission, lower limb arteries were routinely and
anatomically evaluated by duplex ultrasound. For assessment ofgenerally measured on the dorsal and plantar sides of the foot. In the
SPP test, which uses a laser Doppler instrument (PAD 3000;
Väsamed, Inc., Eden Prairie, MN, USA) to quantitatively evaluate
microcirculatory perfusion in the skin, a laser Doppler sensor is
located beneath a pressure cuff for application and release of pres-
sure to the limb. All patients also underwent digital subtraction
angiography before the procedure. A consensus of vascular special-
ists, including vascular surgeons, interventional cardiologists and
radiologists, judged whether EVT was indicated for each patient.
Because 98% of lesions were Transatlantic Inter-Society Consensus
(TASC) 2000 D in an infrapopliteal artery, indication for EVT was
decided by consensus depending on lower limb severity and general
condition based on our published risk stratiﬁcation.10
All EVT procedures were performed under local anesthesia by
a cardiologist or vascular surgeon. Anatomical indicationwas judged
by digital subtraction angiography, and lesions with 75% diameter
stenosis were treated. Selection of EVT approach was left to the
operator’s discretion. Generally, a 3Fr 55 cm sheath (Medkit, Japan)
was used for the antegrade approach from the ipsilateral common
femoral artery. After placing the sheath, unfractionated heparin
(5000 units) was routinely injected into the artery. A 0.014-inch
guide wire was advanced into the culprit lesion and an optimally
sized balloon catheter was introduced. For treatment of chronic total
occlusion (CTO), the intraluminal approach was generally used, with
the subintimal approach with wire loop technique being used in
cases of failed wire crossing. Vessel diameter and lesion length were
visually assessed using preprocedural duplex and the balloon cath-
eter as reference. A 100mm or 120mm balloonwas commonly used
and balloon inﬂation was held at nominal pressure for at least 180 s.
Stent and atherectomy devices were not approved for use in infra-
popliteal intervention in Japan. Angiosome-based intervention was
done for the target lesion and, if an angiosome-based straight line
was obtained, other lesions with residual stenosis were not treated.
However, if treatment of the angiosome-based target lesion was
unsuccessful, a non-angiosome-based lesion was treated. Dual
antiplatelet therapy (aspirin at 100 mg/day and either ticlopidine at
200 mg/day or cilostazol at 200 mg/day) was started at least 1 week
prior to EVT and continued lifelong.
Follow-up and outcomes
All patients were followed up at 1 week, 1, 2, and 3 months after
revascularization, and thereafter every 3 months until 12 months.
All patients had follow-up angiography scheduled at 3 months after
balloon angioplasty. Additionally, to assess the 12-month restenosis
rate, 12-month angiography follow-up was scheduled for patients
without angiographic restenosis at 3 months. If a patient did not
return to the hospital, phone calls were made to check limb status
and the patient’s general health. All patients with open ulcers were
individually followed and complete wound healing was judged by
a plastic surgeon. Severity of wounds before revascularization,
especially of those involving infection and extension, was carefully
assessed by a plastic surgeon who decided indication for antibiotic
therapy and amputation timing. Duplex, ABI and SPP were
routinely measured before and after the EVT procedure as the
standard assessment modality for limb healing or worsening.
Deﬁnitions
Ischemic tissue loss was deﬁned in accordance with TASC as
tissue loss associated with an ankle pressure <70 mmHg or a toe
pressure <50 mmHg. When these measurements could not be
obtained due to intractable rest pain or a non-compressible artery
Figure 1. Participant ﬂow through the J-BEAT angio registry.
Table 1
Overall patient characteristics.
Age 75  8
Male gender 57% (36)
BMI (body mass index) 22  3
Patient ADL (ambulatory/wheelchair/bedridden)
before angioplasty
30/31/2
Risk factors
Hypertension 79% (50)
Hyperlipidemia 41% (26)
Diabetes mellitus 62% (39)
Current smoking 25% (16)
ESRD (GFR<15)/regular dialysis 60% (38)/57% (36)
Cardiovascular disease
Coronary artery disease 43% (27)
Ejection fraction (%) 60  13
Cerebrovascular disease 19% (12)
Medications
Antibiotics 27% (17)
Cilostazol 51% (32)
Statin 27% (17)
Tissue loss 85% (58)
ABI before angioplasty 0.74  0.17
SPP (dorsal side/plantar side) mmHg
before angioplasty 28  15/33  18
after angioplasty 47  28/48  21
at 3 months 43  19/43  22
C-reactive protein level (mg/dL) 1.9  2.7
Lesion characteristics
TASC D lesion 98% (64)
Reference vessel diameter (mm) 2.4  0.4
Lesion length (mm) 140  90
% Diameter stenosis (pre/post/3 months) 97  9/27  17/74  36
Residual stenosis greater than 30% diameter
stenosis just after angioplasty
19% (19)
Chronic total occlusion (pre/3 months) 62% (63)/ 30% (31)
Vessel calciﬁcation 49% (52)
ADL: activity daily life.
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plantar sides of the foot. An SPP <40 mmHg was deﬁned as indi-
cating ischemic tissue loss.11 Atherosclerosis risk factors have been
reported previously.12 Coronary artery disease was deﬁned as
history of any revascularization of the coronary arteries. Cerebro-
vascular disease was deﬁned as a history of stroke and/or cerebral
hemorrhage. End-stage renal disease (ESRD) was deﬁned as
a glomerular ﬁltration rate (GFR) <15 L/min/1.73 m2 or regular
dialysis. EVT procedural success was deﬁned as obtaining one
straight-line ﬂow to the ulcer or gangrene region without occur-
rence of any ﬂow limiting dissection. EVT with angioplasty was
considered hemodynamically successful when post-procedural SPP
level increased by more than 40 mmHg, which is associated with
a high limb salvage rate. Reintervention included repeat angio-
plasty. Below the knee, above the knee and forefoot amputation
was deﬁned as major amputation. Ambulatory status was deﬁned
as being capable of walking and this was judged by a physical
therapist.
Study endpoints
Primary study endpoint was 3-month angiographic binary
restenosis rate per lesion. Follow-up angiography in two different
angulations was performed using an antegrade approach via a 3 Fr
sheath. Angiograms were analyzed on site by two investigators
based on visual estimation. Binary restenosis was calculated using
a 50% diameter reduction threshold. Secondary endpoints were 12-
month angiographic binary restenosis rate, 3- and 12-month
mortality, freedom from ischemic symptoms and reintervention
rate. Additionally, we classiﬁed the overall patient and limb pop-
ulations into two groups based on the presence/absence of 3-
month angiographic restenosis, and subsequently compared
frequency of ambulatory status, frequency of freedom from
ischemic symptoms at 3 and 12months, and time towound healing
in the ischemicwound group during the chronic phase. Also, factors
associated with angiographic restenosis were assessed by multi-
variable analysis. Follow-up angiography was scheduled at 3
months for all participants and at 12months for patients without 3-
month angiographic restenosis after balloon angioplasty.
Statistical analysis
Data are shown as means  standard deviation. An unpaired t-
test was used to compare continuous variables with normal
distributions. Chi-square test was used to compare proportions
between groups. Statistical signiﬁcance level was set at p < 0.05.
Independent outcome determinants were determined by multi-
variable analysis including all univariable parameters with a p-
value of <0.10. Statistical analysis was performed using SPSS (SPSS
Inc., Chicago, IL, USA).
Results
Participant ﬂow through the trial
Fig. 1 shows participant ﬂow through the trial. Sixty-three
consecutive patients (109 infrapopliteal arteries in 68 limbs) were
enrolled in this study between January and March 2011 with last
follow-up completed inMarch 2012. Timing of the 3-month follow-
up ranged from April to July 2011. Complete clinical follow-up at 3
months was available for all study participants except for those
who had died. Three patients with 3 limbs and 7 infrapopliteal
lesions could not be assessed because they died before the sched-
uled 3-month follow-up angiography, and follow-up angiography
was consequently conducted in 95% (60/63) of study participants.Five patients died after 3-month angiography and 60 limbs in 55 CLI
patients underwent a 12-month clinical follow-up.Overall characteristics
Overall patient characteristics are shown in Table 1. Sixty-two
percent (39/63) of patients suffered from diabetes mellitus and
57% (36) had ESRD on dialysis. Eighty-ﬁve percent of limbs (58/68)
were complicated with tissue loss deﬁned as Rutherford 5 or 6. ABI
was slightly decreased at 0.74 but SPP level was insufﬁcient for
ulcer healing. Average treated lesion length was 140 mm, and 98%
(64/65) of lesions were deﬁned as TASC 2000 D. Because of inclu-
sion of a high number of patients with diabetes mellitus and ESRD
Figure 2. Outcomes at 3 and 12 months.
Table 2
Multivariate analysis for angiographic restenosis at 3 months.
Variables Adjusted odds ratio [95% CI] p value
Hypertension 0.090 [0.014, 0.587] 0.012
Administration of cilostazol 0.299 [0.107, 0.834] 0.021
Administration of statin 0.168 [0.048, 0.590] 0.005
Lesion length (mm) 1.002 [0.996, 1.009] 0.439
Chronic total occlusion 4.809 [1.651, 14.01] 0.004
Multivariate logistic regression analysis was performed.
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readily visible densities noted within the apparent vascular wall by
angiography. Forty-eight percent (30/63) of patients were ambu-
latory before angioplasty.Table 3
Comparison of characteristics between patients with and without 3 months
angiographic restenosis.
Patients with
restenosis
(n ¼ 46)
Patients
without
restenosis
(n ¼ 14)
p value
Patient statusOutcomes at 3 months
Outcomes at 3 months are shown in Fig. 2. Three-month angio-
graphic restenosis as primary endpoint was found in 73% (74/102) of
lesions. At 3 months after angioplasty, 32% (21/65) of limbs lacked
complete ulcer healing or had rest pain recurrence, and 40% (26/65)
of limbs had undergone reintervention using angioplasty. Five limbs
required reintervention because of subcritical limb ischemia with
severe stenosis. Fig. 3 shows the ﬁndings in the 102 lesions angio-
graphically assessed at 3 months. At baseline, there were 39 stenotic
and 63 occlusive lesions. In the stenosis group, 41% (16/39) of lesions
did not develop angiographic restenosis at 3 months while 51%
(20/39) of lesions had restenosis and 8% (3/39) of lesions were re-
occluded. In the occlusion group, 19% (12/63) of lesions did not
develop angiographic restenosis at 3 months while 49% (31/63) of
lesions re-occluded and 32% (20/63) of lesions had restenosis.
Distributions were signiﬁcantly different among groups. Table 2
shows predictors for 3-month angiographic restenosis. AfterFigure 3. Findings in the 102 lesions angiographically assessed at 3 months.multivariate logistic regression analysis, administration of cilostazol
(adjusted odds ratio: 0.299, 95% conﬁdential interval [CI]:
0.107e0.834; p ¼ 0.021) and statin (adjusted odds ratio: 0.168, 95%
CI: 0.048e0.590; p ¼ 0.0005) was negatively associated while CTO
(adjusted odds ratio, 4.809; 95% CI: 1.651e14.01; p ¼ 0.004) was
positively associated with 3-month restenosis.Comparison of characteristics between patients and limbs with and
without 3-month angiographic restenosis
Comparison of characteristics between patients with and
without restenosis is shown in Table 3. There were no signiﬁcant
differences in distribution of atherosclerosis risk factors and
comorbidities, except for administration of cilostazol. Fig. 4 shows
the comparison of frequency before angioplasty, and at 3 and 12
months, of ambulatory status between patients with and without
restenosis. Frequency of ambulatory status before angioplasty and 3
months later was not signiﬁcantly different between patients with
and without restenosis (before angioplasty: 48% vs. 57%, p¼ 0.54; 3
months: 54% vs. 64%, p ¼ 0.51). However, frequency of ambulatory
status at 12months was greater in the non-restenosis group than in
the restenosis group (92% vs. 55%, p ¼ 0.04). Regarding comparison
of characteristics between limbs with and without restenosis inAge 74  8 77  8 0.21
Male 52% (24) 71% (10) 0.24
BMI 22  3 23  3 0.77
Patient ADL (ambulatory/
wheelchair/bedridden)
before angioplasty
22/22/2 8/6/0 0.85
Patient ADL (ambulatory/
wheelchair/bedridden)
at 3 months
25/19/2 9/4/1 0.81
Patient ADL (ambulatory/
wheelchair/bedridden)
at 12 months
24/17/1 12/1/0 0.07
Risk factors
Hypertension 76% (35) 86% (12) 0.44
Hyperlipidemia 41% (19) 50% (7) 0.57
Low-density lipoprotein 101  38 90  28 0.33
Diabetes mellitus 59% (27) 64% (9) 0.71
HbA1c 6.2  1.4 6.4  1.8 0.67
ESRD on dialysis 52% (24) 64% (9) 0.43
Coronary artery disease 41% (19) 43% (6) 0.99
Ejection fraction (%) 59  14 64  9 0.28
Cerebrovascular disease 17% (8) 11% (1) 0.35
Medication
Cilostazol 39% (18) 71% (10) 0.03
Statin 26% (12) 43% (6) 0.23
Figure 4. Comparison of frequency of ambulatory status between patients with and
without restenosis before angioplasty, and after 3 and 12 months.
Figure 5. Comparison of frequency of complete ulcer healing or lack of rest pain with
and without restenosis after 3 and 12 months.
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and post procedure and 3-month SPP were not signiﬁcantly
different between the restenosis and non-restenosis groups.
However, 3-month SPP at both dorsal and plantar sides was
numerically lower in the restenosis than in the non-restenosis
group. SPP > 40 mmHg, indicative of sufﬁcient blood ﬂow for
ulcer healing, at the plantar side was more frequently observed in
the non-restenosis group than the restenosis group. Twelve-month
reintervention rate was 59% in the limbs with 3-month angio-
graphic restenosis. Fig. 5 shows the comparison of frequency at 3
months and 12months of complete ulcer healing or lack of rest pain
in limbs with and without restenosis. Frequency of complete ulcer
healing or lack of rest pain was higher in the non-restenosis group
than in the restenosis group at 3 months (100% vs. 59%, p¼ 0.0035).
The same tendency was observed at 12 months but the difference
did not reach statistical signiﬁcance (100% vs. 81%, p ¼ 0.09).
Eighty-three percent (54/65) of limbs had Rutherford 5/6 status
before angioplasty and 7% (4/55) of ischemic wounds were not
completely healed at 12 months. In limbs with complete wound
healing (n ¼ 51) in the chronic phase, average time to wound
healing in the overall population was 112  79 days, and it was
longer in the restenosis group than in the non-restenosis group
(127  83 vs. 66  40 days, p ¼ 0.02).Table 4
Comparison of characteristics between lower limbs with and without restenosis.
Limbs with
restenosis (n ¼ 51)
Tissue loss 84% (43)
C-reactive protein level (mg/dL) 2.0  2.7 [1.9]
Wound infection 26% (13)
TASC 2000 classiﬁcation C/D 2/49
ABI 0.73  0.16
SPP (dorsal side/plantar side) mmHg
before angioplasty 28  15/34  18
after angioplasty 47  22/46  21
at 3 months 41  19/40  23
SPP >40 mmHg before/after/at
3 months (dorsal side)
18% (9)/53% (27)/
47% (24)
SPP >40 mmHg before/after/at
3 months (plantar side)
29% (15)/57% (29)/
44% (19)
Time to wound healing (days) 127  83
12 Months reintervention rate 59% (30)Outcomes at 12 months
Fig. 2 shows the 12-month outcomes. Fourteen limbs in 14
patients were free from 3-month angiographic restenosis and one
of these patients died within 12 months. Two patients were lost to
12-month angiographic follow-up and therefore 85% of limbs
(11/13) with 23 lesions underwent 12-month angiographic follow-
up. Twelve-month angiographic restenosis as secondary endpoint
was present in 82% (81/99) of lesions. At 12 months after angio-
plasty, 15% (9/60) of limbs lacked complete ulcer healing or had rest
pain recurrence, and 48% (31/65) of limbs had undergone reinter-
vention using angioplasty. At 3 and 12 months, no patients had
undergone major amputation.Discussion
Our prospective and multicenter registry examined the 3-
month angiographic restenosis rate after infrapopliteal angio-
plasty for patients with CLI. Three-month angiographic follow-up
was conducted in 95% (60/63) of cases and the restenosis rate
was 73% (74/102). By multivariable analysis for predictors of 3-
month angiographic restenosis, non-administration of cilostazol
and statin, and CTO were positively associated with angiographicLimbs without
restenosis (n ¼ 14)
p value
79% (11) 0.69
1.9  3.1 [0.95] 0.84
29% (4) 0.99
1/13 0.37
0.76  0.17 0.51
30  15/33  20 0.66/0.86
48  10/55  23 0.88/0.18
49  18/50  19 0.18/0.23
31% (4)/77% (10)/77% (10) 0.29/0.21/0.09
39% (5)/69% (9)/75% (14) 0.53/0.42/0.05
66  40 0.02
7% (1) 0.0006
O. Iida et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 425e431430restenosis. At 3months limbswith incomplete ulcer healing or with
rest pain recurrence and at 12 months patients with non-
ambulatory status were more frequently observed in the reste-
nosis group.
Based on results from a meta-analysis, although technical
success and subsequent durability of infrapopliteal angioplasty are
limited in comparison to bypass surgery, clinical beneﬁt is
acceptable because limb salvage rates are similar between the two
treatment modalities.13 Therefore, occurrence of restenosis
appeared not to affect limb salvage, leading to a perceived lack of
relevance of durability of infrapopliteal angioplasty in the clinical
setting. However, results from this prospective multicenter
registry indicate that occurrence of restenosis during the wound-
healing process after angioplasty for patients with CLI will delay
or hinder ischemic wound healing and achievement of ambulatory
status in the chronic phase. Therefore, it adversely impacts
improvement of clinical outcomes in CLI patients. In this study,
the 3-month angiographic restenosis rate was slightly higher than
found in earlier studies.9 This might be attributed to the fact that
more than half the patients were on dialysis therapy, leading to
a more severe form of atherosclerosis complicated by calciﬁcation.
Regarding factors associated with restenosis, there is general
agreement that restenosis is more frequently observed in lesions
with CTO than in those without it.14,15 However, from the angio-
graphic perspective, presence of CTO is a novel predictor for
restenosis after infrapopliteal angioplasty. Cilostazol and statins
have an inhibitory effect on restenosis after percutaneous coro-
nary intervention, and several studies in patients with peripheral
artery disease identiﬁed improvement of walking distance in
intermittent claudication,14e16 and reduction of restenosis after
femoropopliteal stenting and of need for revascularization in
claudicant patients.17e19 It could be speculated that antiprolifera-
tion of vascular smooth muscle cells and improvement of endo-
thelial cell function with cilostazol and statin therapy may lead to
inhibition of neointimal hyperplasia following balloon angioplasty
for infrapopliteal lesions.20,21 Recently, cilostazol and statins were
shown to improve amputation-free survival and limb salvage rate
after EVT for infrainguinal disease in patients with CLI.20,21
Therefore, these results favor use of cilostazol and statin as ﬁrst-
line oral drugs for patients with CLI treated by infrapopliteal
angioplasty.
Limitations
There were several limitations to this study. Although this was
a prospective and multicenter study, it included a small number of
CLI patients. Also, control groups of patients who were unsuitable
for revascularization and patients treatedwith bypass therapywere
not included because we did not manage those cases. Quantitative
vascular analysis to evaluate the degree of restenosis in long
infrapopliteal lesions was not conducted because it is technically
and clinically challenging. Therefore, visual assessment by angi-
ography was used to precisely determine binary restenosis. Finally,
selection of medication, especially antiplatelet therapy, was
decided by physicians’ prescription leading to a risk of selection
bias.
Long-term efﬁcacy outcomes of traditional angioplasty have
been systematically studied and found to be comparable to those
of BSX.8 Consequently, occurrence of restenosis after infrapopliteal
angioplasty has not been generally considered as a critical issue
after an endovascular approach for patients with CLI. To the best
of our knowledge, this is the ﬁrst report on the relationship
between restenosis after angioplasty and clinical outcomes in
patients with CLI due to isolated infrapopliteal lesions. A
randomized trial with a large number of patients to investigatethe long-term clinical efﬁcacy of next-generation infrapopliteal
devices is warranted.
Conclusion
The 3-month restenosis rate of diseased infrapopliteal arteries
was extremely high after treatment with plain balloon angio-
plasty. Occurrence of restenosis in the early phase may adversely
impact improvement of clinical outcomes after endovascular
intervention.
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